GlassScriptPhysician profile
Hoa P Nguyen
NPI 1528083664
$3,980.76
in general payments reported to CMS, 2019-2025
29 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $58.56 · 2021: $67.20 · 2022: $906 · 2023: $1,314 · 2024: $152 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.80 |
| Education | $219.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.50 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Seagen INC. | $409.81 | 2022-2023 | Tukysa |
| Pfizer INC. | $405.10 | 2021-2025 | |
| Janssen Biotech, INC. | $388.27 | 2020-2025 | Carvykti, Rybrevant, Erleada |
| Amgen INC. | $331.16 | 2022-2025 | Lumakras |
| Astellas Pharma US INC | $245.88 | 2025 | Vyloy, Padcev |
| Jazz Pharmaceuticals INC. | $149.99 | 2023 | |
| Incyte Corporation | $140.14 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Emd Serono, INC. | $124.94 | 2022 | |
| Allergan, INC. | $124.93 | 2019 | |
| Glaxosmithkline, LLC. | $119.23 | 2025 | Zejula |
| Daiichi Sankyo INC. | $112.30 | 2023 | Injectafer |
| Teleflex LLC | $102.93 | 2024 | |
| Eisai INC. | $82.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $80.67 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $37.59 | 2023-2025 | Mektovi, Braftovi, Paxlovid |
| Lilly USA, LLC | $30.25 | 2023 | Verzenio |
| Merck Sharp & Dohme LLC | $28.93 | 2023 | Keytruda |
| Tempus Ai, INC | $24.67 | 2024 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $23.95 | 2022 | |
| Genzyme Corporation | $23.71 | 2025 | |
| Novocure INC. | $23.20 | 2025 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $20.81 | 2023 | Opdivo |
| Genentech USA, INC. | $19.37 | 2022 | |
| Abbvie INC. | $18.64 | 2023 | |
| Collegium Pharmaceutical, INC. | $17.25 | 2020 | |
| Celgene Corporation | $16.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.03 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoa Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.